Literature DB >> 17567478

Non-alcoholic steatohepatitis and hepatocellular carcinoma: lessons from hepatocyte-specific phosphatase and tensin homolog (PTEN)-deficient mice.

Sumio Watanabe1, Yasuo Horie, Ei Kataoka, Wataru Sato, Takahiro Dohmen, Shigetoshi Ohshima, Takashi Goto, Akira Suzuki.   

Abstract

Non-alcoholic steatohepatitis (NASH) is a term used to describe a spectrum of conditions characterized by histological findings of hepatic macrovesicular steatosis with inflammation in individuals who consume little or no alcohol. The NASH patients progress to liver cirrhosis and even hepatocellular carcinoma (HCC). Hepatocyte-specific phosphatase and tensin homolog (PTEN)-deficient mice (PTEN-deficient mice), which the authors had generated previously, showed massive hepatomegaly and steatohepatitis with triglyceride accumulation followed by liver fibrosis and HCC, a phenotype similar to human NASH. Therefore, it was shown that PTEN deficiency in hepatocytes could induce hepatic steatosis, inflammation, fibrosis and tumors and that PTEN-deficient mice were a useful animal model for not only the understanding of the pathogenesis of NASH but also the development of treatment for NASH.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17567478     DOI: 10.1111/j.1440-1746.2006.04665.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  26 in total

Review 1.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

Review 2.  miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma.

Authors:  Weiqi Tan; Yang Li; Seng-Gee Lim; Theresa M C Tan
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

3.  Mice deficient in glycerol-3-phosphate acyltransferase-1 have a reduced susceptibility to liver cancer.

Authors:  Jessica M Ellis; David S Paul; Michael A Depetrillo; Bhanu P Singh; David E Malarkey; Rosalind A Coleman
Journal:  Toxicol Pathol       Date:  2012-01-03       Impact factor: 1.902

Review 4.  New insights in hepatocellular carcinoma: from bench to bedside.

Authors:  Samuele De Minicis; Marco Marzioni; Antonio Benedetti; Gianluca Svegliati-Baroni
Journal:  Ann Transl Med       Date:  2013-07

Review 5.  Epidemiology and surveillance of hepatocellular carcinoma.

Authors:  Do Young Kim; Kwang-Hyub Han
Journal:  Liver Cancer       Date:  2012-06       Impact factor: 11.740

6.  Development of novel rat model for high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis progression in SHRSP5/Dmcr.

Authors:  Kazuya Kitamori; Hisao Naito; Hazuki Tamada; Miya Kobayashi; Daisuke Miyazawa; Yuko Yasui; Kunihiro Sonoda; Satoru Tsuchikura; Naomi Yasui; Katsumi Ikeda; Takashi Moriya; Yukio Yamori; Tamie Nakajima
Journal:  Environ Health Prev Med       Date:  2011-08-19       Impact factor: 3.674

Review 7.  Mammalian target of rapamycin inhibition in hepatocellular carcinoma.

Authors:  René E Ashworth; Jennifer Wu
Journal:  World J Hepatol       Date:  2014-11-27

Review 8.  Genetically modified mouse models for the study of nonalcoholic fatty liver disease.

Authors:  Perumal Nagarajan; M Jerald Mahesh Kumar; Ramasamy Venkatesan; Subeer S Majundar; Ramesh C Juyal
Journal:  World J Gastroenterol       Date:  2012-03-21       Impact factor: 5.742

Review 9.  The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology.

Authors:  Stephen Caldwell; Sang H Park
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

Review 10.  Experimental mouse models for hepatocellular carcinoma research.

Authors:  Femke Heindryckx; Isabelle Colle; Hans Van Vlierberghe
Journal:  Int J Exp Pathol       Date:  2009-08       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.